Charting psychedelic stocks

Mapping the psychoactive equity market

Stacked market cap of major psychedelic stocks

A “psychedelic renaissance” has emerged in recent years, while associated biotech firms have seen a remarkable boom and bust. Multiple publicly-traded companies are pursuing Phase 1, 2, and 3 trials testing psilocybin, DMT, LSD, and more.

Rising research across both private and public sectors show psychedelic potential for treating depression, PTSD, addiction, and beyond. While the sector is extremely speculative, billions of dollars are lined up to capitalize on psychedelic IP and broader regulatory breakthroughs.

Major publicly-traded psychedelic stocks snapshot

Psychedelic stock development

• Mind Medicine (MNMD): Upcoming Phase 3 trials using an LSD analogue for general anxiety. Plus Phase 1 using MDMA for autism.
• GH Research (GHRS): Ongoing Phase 2 trials using a 5-MeO-DMT analogue for treatment-resistant depression, bipolar, and postpartum depression.
• ATAI Life Sciences (ATAI): Ongoing Phase 2 trials using a DMT analogue for treatment-resistant depression, plus Phase 1s using MDMA for social anxiety and ibogaine for opioid addiction. (Also holds strategic…